SG11201913236QA - 5-membered and bicyclic heterocyclic amides as inhibitors of rock - Google Patents
5-membered and bicyclic heterocyclic amides as inhibitors of rockInfo
- Publication number
- SG11201913236QA SG11201913236QA SG11201913236QA SG11201913236QA SG11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA SG 11201913236Q A SG11201913236Q A SG 11201913236QA
- Authority
- SG
- Singapore
- Prior art keywords
- membered
- rock
- inhibitors
- bicyclic heterocyclic
- heterocyclic amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531563P | 2017-07-12 | 2017-07-12 | |
PCT/US2018/041573 WO2019014308A1 (en) | 2017-07-12 | 2018-07-11 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201913236QA true SG11201913236QA (en) | 2020-01-30 |
Family
ID=63036489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201913236QA SG11201913236QA (en) | 2017-07-12 | 2018-07-11 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock |
Country Status (19)
Country | Link |
---|---|
US (2) | US11078197B2 (en) |
EP (1) | EP3652168B1 (en) |
JP (1) | JP7206252B2 (en) |
KR (1) | KR20200028423A (en) |
CN (1) | CN110869363B (en) |
AR (1) | AR112273A1 (en) |
AU (1) | AU2018300094A1 (en) |
BR (1) | BR112020000284A2 (en) |
CA (1) | CA3069311A1 (en) |
CL (1) | CL2019003747A1 (en) |
CO (1) | CO2019014455A2 (en) |
EA (1) | EA202090256A1 (en) |
ES (1) | ES2882432T3 (en) |
IL (1) | IL271905B (en) |
PE (1) | PE20200388A1 (en) |
SG (1) | SG11201913236QA (en) |
TW (1) | TW201908293A (en) |
WO (1) | WO2019014308A1 (en) |
ZA (1) | ZA202000877B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102491994B1 (en) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Spirolactam as an inhibitor of ROCK |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
TW201908293A (en) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine |
US11306081B2 (en) | 2017-07-12 | 2022-04-19 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
ES2894128T3 (en) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure |
US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
ES2937039T3 (en) | 2017-11-03 | 2023-03-23 | Bristol Myers Squibb Co | ROCK Diazaspiro Inhibitors |
JP2021526123A (en) * | 2018-05-29 | 2021-09-30 | シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー. | Autotaxin inhibitors and their use |
US10711000B2 (en) | 2018-05-29 | 2020-07-14 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
MX2021005273A (en) | 2018-11-06 | 2021-09-08 | Cervello Therapeutics LLC | Rock kinase inhibitors. |
US11248004B2 (en) | 2018-11-06 | 2022-02-15 | Cervello Therapeutics, Llc. | Substituted isoquinolines as rock kinase inhibitors |
CA3226468A1 (en) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Microbiocidal pyrazole derivatives |
WO2023129512A1 (en) * | 2021-12-31 | 2023-07-06 | President And Fellows Of Harvard College | Bicyclic inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof |
WO2024013736A1 (en) * | 2022-07-12 | 2024-01-18 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
US20240092755A1 (en) * | 2022-08-16 | 2024-03-21 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8227480B2 (en) | 2006-06-08 | 2012-07-24 | Ube Industries, Ltd. | Indazole derivative having spiro ring structure in side chain |
ES2729424T3 (en) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Rho kinase inhibitors |
CL2007003874A1 (en) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION |
CA2737738A1 (en) * | 2008-09-18 | 2010-03-25 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
SG10202010119TA (en) | 2010-11-15 | 2020-11-27 | Abbvie Inc | NAMPT And Rock Inhibitors |
ES2684776T3 (en) | 2013-01-18 | 2018-10-04 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as ROCK inhibitors |
CN105102448B (en) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | Phenylpyrazole derivatives as ROCK1 and ROCK2 inhibitor |
AR094929A1 (en) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2 |
TW201506024A (en) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | Tricyclic carboxamide derivatives as potent ROCK inhibitors |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
JP6779214B2 (en) | 2015-01-09 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cyclic urea as a ROCK inhibitor |
EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
AR107354A1 (en) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | SPIROHEPTAN SALICILAMIDS AND RELATED COMPOUNDS AS ROCK INHIBITORS |
CN109153663B (en) | 2016-05-27 | 2021-08-13 | 百时美施贵宝公司 | Triazolones and tetrazolones as ROCK inhibitors |
KR102491994B1 (en) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Spirolactam as an inhibitor of ROCK |
EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
CN110049977B (en) | 2016-07-07 | 2022-01-18 | 百时美施贵宝公司 | Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
TW201908293A (en) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine |
ES2894128T3 (en) | 2017-07-12 | 2022-02-11 | Bristol Myers Squibb Co | ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure |
US11306081B2 (en) | 2017-07-12 | 2022-04-19 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
ES2937039T3 (en) | 2017-11-03 | 2023-03-23 | Bristol Myers Squibb Co | ROCK Diazaspiro Inhibitors |
-
2018
- 2018-07-10 TW TW107123859A patent/TW201908293A/en unknown
- 2018-07-11 EP EP18746517.4A patent/EP3652168B1/en active Active
- 2018-07-11 CA CA3069311A patent/CA3069311A1/en active Pending
- 2018-07-11 AR ARP180101933 patent/AR112273A1/en unknown
- 2018-07-11 IL IL271905A patent/IL271905B/en unknown
- 2018-07-11 ES ES18746517T patent/ES2882432T3/en active Active
- 2018-07-11 EA EA202090256A patent/EA202090256A1/en unknown
- 2018-07-11 AU AU2018300094A patent/AU2018300094A1/en not_active Abandoned
- 2018-07-11 US US16/629,717 patent/US11078197B2/en active Active
- 2018-07-11 CN CN201880045773.8A patent/CN110869363B/en active Active
- 2018-07-11 PE PE2019002591A patent/PE20200388A1/en unknown
- 2018-07-11 BR BR112020000284-4A patent/BR112020000284A2/en not_active Application Discontinuation
- 2018-07-11 KR KR1020207003728A patent/KR20200028423A/en active IP Right Grant
- 2018-07-11 WO PCT/US2018/041573 patent/WO2019014308A1/en unknown
- 2018-07-11 SG SG11201913236QA patent/SG11201913236QA/en unknown
- 2018-07-11 JP JP2020501316A patent/JP7206252B2/en active Active
-
2019
- 2019-12-19 CO CONC2019/0014455A patent/CO2019014455A2/en unknown
- 2019-12-19 CL CL2019003747A patent/CL2019003747A1/en unknown
-
2020
- 2020-02-11 ZA ZA2020/00877A patent/ZA202000877B/en unknown
-
2021
- 2021-06-17 US US17/349,980 patent/US11673886B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA202090256A1 (en) | 2020-05-22 |
US11078197B2 (en) | 2021-08-03 |
CN110869363B (en) | 2024-01-05 |
TW201908293A (en) | 2019-03-01 |
IL271905A (en) | 2020-02-27 |
EP3652168B1 (en) | 2021-06-30 |
WO2019014308A1 (en) | 2019-01-17 |
AU2018300094A1 (en) | 2020-02-27 |
ZA202000877B (en) | 2021-08-25 |
US20210147406A1 (en) | 2021-05-20 |
IL271905B (en) | 2022-08-01 |
CA3069311A1 (en) | 2019-01-17 |
ES2882432T3 (en) | 2021-12-01 |
US11673886B2 (en) | 2023-06-13 |
JP2020526556A (en) | 2020-08-31 |
CO2019014455A2 (en) | 2020-01-17 |
CL2019003747A1 (en) | 2020-05-15 |
BR112020000284A2 (en) | 2020-07-14 |
EP3652168A1 (en) | 2020-05-20 |
PE20200388A1 (en) | 2020-02-24 |
KR20200028423A (en) | 2020-03-16 |
US20220356179A1 (en) | 2022-11-10 |
AR112273A1 (en) | 2019-10-09 |
JP7206252B2 (en) | 2023-01-17 |
CN110869363A (en) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202000877B (en) | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | |
IL267090A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
SG11202010822SA (en) | Substituted heterocyclic inhibitors of ptpn11 | |
HK1259232A1 (en) | Substituted inhibitors of menin-mll and methods of use | |
EP3463343A4 (en) | Heterocyclic inhibitors of ptpn11 | |
IL260448B (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
IL270844A (en) | Novel inhibitors of map4k1 | |
IL279949A (en) | Heterocyclic inhibitors of mct4 | |
IL271109A (en) | Imidazole-containing inhibitors of alk2 kinase | |
EP3609882A4 (en) | Heterocyclic inhibitors of pcsk9 | |
IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
IL254430A0 (en) | Heterocyclic compounds useful as inhibitors of tnf | |
HK1248684A1 (en) | Usp7 inhibitor compounds and methods of use | |
PT3458448T (en) | Methods of using fasn inhibitors | |
HK1231484A1 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 tnks1 / tnks2 | |
IL273974A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof | |
IL272190A (en) | Inhibitors of ror gamma | |
EP3697419A4 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof | |
GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
PL3362450T3 (en) | N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis | |
HK1251560A1 (en) | Crystals of thiadiazole derivative dpp-iv inhibitors and uses thereof | |
AU2017900935A0 (en) | Heterocyclic inhibitors of PCSK9 |